Company Overview
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology. TriKE® therapeutic agents are targeted immunotherapeutic agents that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells.
Recent News
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
Stock Overview
Symbol
GTBP
Exchange
Nasdaq
Market Cap
12.27m
Last Price
$6.80
52-Week Range
$4.9101 - $34.25
09/28/2026 08:00 PM EDT